Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Christopher U. Missling
|
| gptkbp:clinicalTrialPhase |
ANAVEX2-73 Phase 2/3 for Rett syndrome
ANAVEX2-73 Phase 2b/3 for Alzheimer's disease |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
therapies for Parkinson's disease
therapies for Alzheimer's disease therapies for Rett syndrome |
| gptkbp:focusesOn |
neurodegenerative diseases
rare diseases central nervous system diseases |
| gptkbp:foundedYear |
2004
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Anavex Life Sciences Corp.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
ANAVEX2-73
ANAVEX3-71 |
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
sigma-1 receptor modulators
|
| gptkbp:stockSymbol |
gptkb:NASDAQ
AVXL |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.anavex.com/
|
| gptkbp:bfsParent |
gptkb:ANX
|
| gptkbp:bfsLayer |
7
|